Bristol-Myers Squibb
BMY
$58.31
+1.74%
Bristol-Myers Squibb Co. is a global biopharmaceutical company that discovers, develops, and markets drugs for therapeutic areas including oncology, cardiovascular, and immunology. It is a market leader in immuno-oncology, with a distinct competitive identity built on a robust portfolio of blockbuster drugs and a deep pipeline. The current investor narrative is dominated by the company's ongoing pivot to offset looming patent expirations on key drugs like Eliquis and Revlimid, with recent attention focused on strong quarterly earnings driven by its newer growth portfolio and regulatory approvals for its flagship product, Opdivo.…
BMY
Bristol-Myers Squibb
$58.31
Related headlines
Investment Opinion: Should I buy BMY Today?
Rating & Thesis: Hold. BMY is a high-yield, deep-value turnaround story with asymmetric risk, but the near-term headwinds from patent expirations and analyst skepticism warrant caution. The core thesis is that the stock's 4.58% yield and low forward P/E of 9.24x provide a margin of safety, but investors must wait for clearer evidence that new product growth can sustainably offset legacy declines before committing new capital.
Supporting Evidence: The Hold rating is supported by four key data points. First, valuation is compelling on a forward basis (P/E of 9.24x) but contested, as the implied analyst target suggests 22% downside. Second, the dividend yield of 4.58% is attractive and currently supported by strong FCF of $12.85B. Third, ROE of 38.18% and gross margins around 67% demonstrate underlying business quality. Fourth, recent quarterly news showed a promising 12% jump in new portfolio sales, providing a glimmer of hope for the pivot narrative.
Risks & Conditions: The two biggest risks are the pace of the patent cliff and the sustainability of the dividend if cash flow erodes. This Hold would upgrade to a Buy if: 1) Sequential revenue growth from new products accelerates consistently above 15%, 2) The forward P/E compresses further toward 8x without an earnings cut, or 3) The stock breaks below $50, offering a higher yield and greater margin of safety. It would downgrade to a Sell if: 1) Quarterly revenue turns negative YoY, 2) The company guides for a dividend cut, or 3) Debt-to-equity rises above 3.0. Currently, the stock appears fairly valued to slightly overvalued relative to near-term analyst expectations, but deeply undervalued if its long-term turnaround succeeds.
Sign up to view all
BMY 12-Month Price Forecast
BMY presents a balanced but risky proposition. The low forward multiple and high yield create a value narrative, but these are directly challenged by the fundamental headwind of patent expirations and analyst pessimism. The neutral stance reflects the high probability (50%) of a muddle-through base case where the stock treads water. Confidence is medium due to the high degree of binary outcomes dependent on quarterly execution. The stance would upgrade to bullish on conclusive evidence that new product sales can drive sustained top-line growth (>3% YoY for two consecutive quarters). It would turn bearish if the stock breaks key technical support near $55 on high volume, signaling a loss of faith in the dividend safety.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bristol-Myers Squibb's 12-month outlook, with a consensus price target around $75.80 and implied upside of +30.0% versus the current price.
Average Target
$75.80
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$47 - $76
Analyst target range
Analyst coverage for BMY is substantial, with 11 analysts providing estimates. The consensus sentiment appears neutral to cautiously optimistic, as reflected in recent institutional ratings which include a mix of 'Buy', 'Overweight', 'Hold', 'Equal Weight', and 'Neutral' actions, with no recent downgrades. The average target price must be derived from estimated metrics; using the estimated EPS average of $4.795 and the forward PE of 9.24 implies a target price of approximately $44.30, which would represent a -22.3% downside from the current price of $57, indicating bearish consensus. The target range, inferred from estimated EPS, shows a low of $4.634 to a high of $4.898. The high target assumes successful execution of the growth pipeline, margin expansion, and manageable impact from patent expirations. The low target likely prices in more severe revenue erosion from key drug losses, pipeline setbacks, and potential margin compression. The relatively tight range between the low and high EPS estimates (a spread of about 5.7%) suggests analysts have a moderate degree of conviction in their near-term earnings forecasts, though the wide dispersion in price targets implied by different valuation multiples points to higher uncertainty regarding the appropriate multiple to apply to those earnings.
Bulls vs Bears: BMY Investment Factors
The investment debate for BMY centers on a classic value vs. value trap tension. The bull case is anchored by a cheap forward P/E of 9.24x, a high 4.58% dividend yield supported by strong cash flow, and early signs of success in its newer growth portfolio. The bear case is dominated by the imminent and severe patent cliff, high financial leverage, and analyst consensus that implies significant downside. Currently, the bearish evidence appears stronger, as the market is pricing in a high probability of earnings deterioration that the new portfolio may not fully offset. The single most important factor is the execution and growth trajectory of the new product portfolio relative to the pace of revenue erosion from Eliquis and Revlimid. If new drug sales accelerate faster than expected, the stock's deep valuation discount could provide substantial upside; if not, the dividend and share price are at risk.
Bullish
- Strong Free Cash Flow & Dividend: BMY generates robust free cash flow of $12.85B TTM, which comfortably supports its attractive 4.58% dividend yield with a payout ratio of 71.5%. This provides a tangible return floor for income-focused investors.
- Successful New Portfolio Growth: Recent Q1 earnings were driven by a 12% jump in sales from the newer growth portfolio, signaling the company's pivot is gaining traction. This is critical to offsetting patent expirations on key drugs like Revlimid.
- Compelling Forward Valuation: The stock trades at a forward P/E of 9.24x, a significant discount to its trailing P/E of 15.61x, implying the market expects a substantial earnings recovery. This valuation appears cheap if the growth pivot succeeds.
- High Return on Equity: BMY delivers a very strong ROE of 38.18%, indicating efficient use of shareholder capital. This high profitability supports continued investment in R&D and shareholder returns.
Bearish
- Looming Major Patent Expirations: The company faces significant revenue headwinds from the loss of exclusivity on blockbuster drugs Eliquis and Revlimid. The recent 1.3% YoY revenue growth underscores the challenge of replacing this income.
- Elevated Financial Leverage: BMY's debt-to-equity ratio of 2.55 is high, indicating significant financial leverage. While cash flow is strong, this debt load increases financial risk, especially if earnings decline.
- Analyst Consensus Implies Downside: The implied analyst target price of ~$44.30 (based on forward EPS and P/E) suggests a -22.3% downside from the current $57 price. This reflects deep skepticism about the stock's near-term valuation.
- Recent Technical Weakness: The stock has underperformed the market sharply, with a -14.58 relative strength over 3 months and a -6.16% price decline. This loss of momentum suggests waning investor confidence.
BMY Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 24.43% 1-year price increase, but is currently experiencing a pullback from recent highs. Trading at a price of $57, it sits at approximately 77% of its 52-week range ($42.52 to $62.89), indicating it has retreated meaningfully from its peak but remains well above its lows, suggesting a consolidation phase after a strong run. Recent momentum has turned negative, with the stock down 1.54% over the past month and down 6.16% over the past three months, diverging sharply from the positive 1-year trend and signaling a loss of short-term bullish momentum, potentially due to profit-taking or sector rotation. The key technical levels are clear, with immediate resistance near the 52-week high of $62.89 and support at the 52-week low of $42.52. A breakout above $62.89 would signal a resumption of the primary uptrend, while a breakdown below the recent lows near $55 could indicate a deeper correction. The stock exhibits low market-relative volatility with a beta of 0.259, meaning it is approximately 74% less volatile than the broader market (SPY), which is significant for risk-averse investors seeking defensive exposure within healthcare. The stock's recent underperformance is highlighted by its relative strength metrics, showing a -7.14 relative strength over one month and a -14.58 relative strength over three months against the SPY, which gained 5.6% and 8.42% over those periods, respectively. This pronounced weakness, combined with a short ratio of 3.08, indicates elevated bearish sentiment and potential for a short-covering rally if positive catalysts emerge, though the current price action suggests caution.
Beta
0.26
0.26x market volatility
Max Drawdown
-17.0%
Largest decline past year
52-Week Range
$43-$63
Price range past year
Annual Return
+23.5%
Cumulative gain past year
| Period | BMY Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +3.3% |
| 3m | -2.4% | +6.9% |
| 6m | +26.9% | +12.4% |
| 1y | +23.5% | +23.4% |
| ytd | +9.1% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BMY Fundamental Analysis
Revenue growth is modest but positive, with the most recent quarterly revenue of $12.502 billion representing a 1.3% year-over-year increase. However, this masks significant quarterly volatility; for instance, Q4 2025 revenue grew 1.3% YoY, but sequentially it was up from $12.222 billion in Q3, indicating some stabilization. The growth is being driven by newer products, as highlighted in recent news of a 12% jump in sales from the newer growth portfolio, which is critical as the company manages the decline of mature brands like Revlimid, which contributed $602 million in the latest segment data. The company is profitable but with fluctuating margins. Net income for Q4 2025 was $1.086 billion, yielding a net margin of 8.7%, a significant improvement from the meager $72 million net income in Q4 2024. Gross margin for the quarter was a healthy 67.23%, consistent with the trailing gross margin of 67.65%. Operating margin was 11.35% for the quarter, showing recovery from pressures seen in prior periods, though it remains below the trailing operating margin of 26.34%, indicating some quarterly expense volatility, particularly in R&D and SG&A. Balance sheet health is a mixed picture, characterized by high leverage but strong cash generation. The debt-to-equity ratio is elevated at 2.55, indicating significant financial leverage. However, the company generates substantial cash, with trailing twelve-month free cash flow of $12.845 billion, providing ample coverage for its dividend (payout ratio of 71.5%) and debt obligations. Return on equity is very strong at 38.18%, and the current ratio of 1.26 suggests adequate short-term liquidity, supporting the view that the company can internally fund its growth initiatives and shareholder returns despite its debt load.
Quarterly Revenue
$12.5B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$12.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BMY Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 15.61x, while the forward PE is significantly lower at 9.24x. This substantial gap implies the market expects a meaningful earnings recovery, with forward earnings estimates of approximately $4.80 per share, compared to the diluted EPS of $0.53 reported for Q4 2025. Compared to industry averages, BMY's valuation presents a complex picture. Its trailing PE of 15.61x is below the typical range for high-growth biopharma but may be reasonable for a mature company facing patent cliffs. The Price-to-Sales ratio of 2.28x and EV-to-Sales of 3.13x are moderate, suggesting the market is not assigning a premium for top-line growth, likely due to the near-term revenue headwinds from exclusivity losses. The stock's 4.58% dividend yield provides a floor to valuation, attracting income-oriented investors. Historically, the current trailing PE of 15.61x sits well below its own recent historical range; for instance, the PE ratio was 25.34x at the end of Q4 2025 and has been as high as 398.48x during periods of abnormally low earnings. This suggests the stock is trading at a discount to its own recent history, which could indicate a value opportunity if the company successfully executes its growth pivot, or it may reflect the market's skepticism about the durability of its earnings amid the patent expiration overhang.
PE
15.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -2x~398x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BMY faces acute financial risk from its elevated debt-to-equity ratio of 2.55, which amplifies the impact of any earnings decline. Operationally, the company is navigating a precarious patent cliff, with blockbusters Eliquis and Revlimid losing exclusivity, threatening a significant portion of its revenue base. While quarterly revenue grew 1.3% YoY, this modest growth masks underlying volatility and the immense challenge of replacing billions in lost sales, as evidenced by the still-material $602 million contribution from the declining Revlimid. The high dividend payout ratio of 71.5%, while covered by current cash flow, becomes vulnerable if free cash flow contracts due to revenue pressure.
Market & Competitive Risks: The primary market risk is valuation compression. Despite a low forward P/E of 9.24x, the stock trades at a premium to implied analyst targets, suggesting the market may still be overestimating future earnings durability. Competitive and regulatory headwinds are persistent, including pricing pressure and the potential for new drug tariffs (as per recent news), though BMY's US-centric sales (~70%) may offer some insulation. The stock's low beta of 0.259 suggests it is defensive but not immune to sector-wide rotations out of pharmaceuticals facing growth challenges. Recent underperformance (-14.58 relative strength vs. SPY over 3 months) indicates the market is already pricing in these concerns.
Worst-Case Scenario: The worst-case scenario involves a faster-than-anticipated decline in legacy drug sales coinciding with pipeline setbacks or slower adoption for new products like Opdivo extensions. This could trigger a simultaneous earnings miss, a dividend cut due to cash flow pressure, and a credit rating downgrade due to high leverage. In this adverse scenario, the stock could re-test its 52-week low of $42.52, representing a -25.4% decline from the current price of $57. A more realistic severe bear case, aligning with the low end of analyst EPS estimates, suggests a downside to approximately $42.80 (using the low EPS of $4.63 and a forward P/E of 9.24x), implying a potential loss of -25%.
FAQ
The key risks are, in order of severity: 1) Patent Expiration Risk: The loss of exclusivity on Eliquis and Revlimid threatens billions in revenue, as seen in the modest 1.3% current YoY growth. 2) Financial Leverage Risk: A high debt-to-equity ratio of 2.55 increases vulnerability to earnings shocks. 3) Dividend Sustainability Risk: A high payout ratio of 71.5% could be threatened if free cash flow declines due to revenue erosion. 4) Execution Risk: The company's future depends on its newer growth portfolio, which must accelerate to offset legacy declines, introducing binary quarterly earnings risk.
The 12-month forecast for BMY is a wide range reflecting high uncertainty. The base case (50% probability) sees the stock trading between $48 and $52, as new growth offsets some legacy declines but fails to drive significant multiple expansion. The bull case (25% probability) targets a retest of the 52-week high at $62.89 and beyond, driven by better-than-expected pipeline execution. The bear case (25% probability) envisions a drop toward the 52-week low of $42.52 if patent losses accelerate. The most likely outcome is the base case, predicated on the assumption that the company's pivot proceeds as planned but without major surprises.
BMY's valuation is dichotomous. On a forward P/E basis of 9.24x, it appears deeply undervalued compared to its own historical trailing P/E of 15.61x and many healthcare peers. However, this low multiple reflects the market's expectation of significant earnings pressure from patent cliffs. When compared to analyst consensus, which implies a price target ~22% below the current $57, the stock looks overvalued. Therefore, it is fairly valued to slightly overvalued relative to near-term consensus but potentially undervalued if the company's long-term growth pivot is more successful than currently priced in.
BMY is a speculative buy for a specific investor profile. For income-focused value investors willing to accept high company-specific risk, the 4.58% dividend yield and low forward P/E of 9.24x may be attractive. However, the implied 22% downside to analyst targets and the looming patent expirations on key drugs make it a risky proposition. It could be a good buy for those who believe the new product portfolio will exceed growth expectations, but it is not a good buy for conservative investors or those seeking stable, low-risk income.
BMY is primarily suitable for a long-term investment horizon of 3-5 years. The company's turnaround narrative and the need to navigate the patent cliff will take multiple quarters, if not years, to fully resolve. Its low beta of 0.259 makes it a defensive holding, but the high company-specific risk from pipeline outcomes makes it unsuitable for short-term trading, where binary earnings reactions can cause sharp volatility. The 4.58% dividend also favors a longer holding period to realize income returns. A minimum holding period of 18-24 months is suggested to assess the success of the growth portfolio pivot.